Abbott Completes $21 Billion Acquisition of Exact Sciences, Becomes Leader in Cancer Diagnostics
ABT is trading near its 52-week low of $105.27 (1.3% above the low) on elevated volume (7.5× avg).
Summary
Abbott Laboratories has completed its $21 billion acquisition of Exact Sciences, significantly expanding its footprint and leadership in the high-growth cancer diagnostics market.
Key Events · M&A and Partnerships · ABT
-
Acquisition Completed
Abbott Laboratories finalized its acquisition of Exact Sciences Corporation on March 23, 2026, for $105.00 per share in cash, following the initial agreement in November 2025.
-
Strategic Market Expansion
This acquisition establishes Abbott as a leader in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments, adding a new growth vertical.
-
Enhanced Product Portfolio
Abbott gains a comprehensive suite of cancer detection and treatment products, including Cologuard, Oncotype DX, Oncodetect, and Cancerguard, along with a robust pipeline.
Analysis · ABT · Life Sciences
Abbott Laboratories has completed its significant acquisition of Exact Sciences Corporation, a strategic move that positions the company as a leader in the rapidly expanding cancer screening and diagnostics market. This $21 billion transaction, initially agreed upon in November 2025 and highlighted in Abbott's recent 10-K, is expected to add a new growth vertical and enhance Abbott's presence in the $60 billion U.S. cancer diagnostics segment. The integration of Exact Sciences' portfolio, including key products like Cologuard and Oncotype DX, provides Abbott with a comprehensive suite of offerings for early cancer detection and personalized treatments. This strategic expansion is a long-term growth driver for Abbott, occurring while the company's stock is trading near its 52-week low, suggesting potential for future upside as the market fully digests the benefits of this acquisition.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 42.1% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABT was trading at $106.67 on NYSE in the Life Sciences sector, with a market capitalization of approximately $183.3B. The 52-week trading range was $105.27 to $139.06. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.